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Abstract. Amyloid- (A) aggregation is a recognized key process in the pathogenesis of Alzheimer’s disease (AD). Misfolded
A peptides self-assemble into higher-order oligomers that compromise membrane integrity, leading to synaptic degeneration
and neuronal cell death. The main aim of this study was to explore whether small-molecule compounds and black tea extract
can protect phospholipid membranes from disruption by A aggregates. We first established a robust protocol for aggregating
A42 peptides into a range of oligomers that efficiently permeabilized small unilamellar liposomes. Next, 15 natural plant
polyphenolic compounds, 8 N′-benzylidene-benzohydrazide (NBB) compounds and black tea extract were assessed for their
ability to antagonize liposome permeabilization by the A42 oligomers. Our data indicates that black tea extract, the flavones
apigenin and baicalein, and the stilbene nordihydroguaiaretic acid (NDGA) are indeed potent inhibitors. Taking into consideration
the results of all the small-molecule polyphenols and NBB compounds, it can be proposed that a dihydroxyphenyl ring structure,
alone or as part of a flavone scaffold, is particularly effective for protection against membrane damage by the A42 oligomers.
Given the critical role of membrane perforation in the neurodegenerative cascade, these conclusions may guide the design and
development of novel therapeutic drugs in AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a major economical
and social burden in the Western world, being the
most common cause of dementia in all age groups
and the fourth common cause of death following car-
diovascular disease, cancer, and stroke [1]. Clinical
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manifestations include a worsening cognitive deficit,
initially limited to memory alone, but which ultimately
interferes with normal social and occupational func-
tioning [2]. Neurodegeneration in AD is relentless and
irreversible, and an effective disease-modifying ther-
apy still remains to be developed.
Nevertheless, great strides have been made in trying
to understand the cellular and molecular mecha-
nisms that induce AD [3]. In particular, a formidable
body of evidence gathered from genetic, biochemical,
and transgenic mouse studies, supports the so-called
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‘amyloid-beta’ (A) hypothesis [4]. Essentially, the
hypothesis centers on the pathological aggregation and
accumulation in the brain of higher-order multimeric
structures derived from monomeric A peptides. The
former are represented by small soluble oligomers,
larger protofibrils, and insoluble amyloid fibrils [5] that
form extracellular plaque deposits, one of the major
pathological hallmarks found in specific regions of
postmortem AD brains [6]. Mutations associated with
increased propensity of A42 peptide to form protofib-
rils correlated nicely with neuronal dysfunction and
degeneration in a Drosophila model of AD, thus lend-
ing strong support to the view that A42 aggregation
is a critical factor driving neuronal dysfunction in AD
[7]. Moreover, accumulating evidence indicates that
neurodegeneration and memory loss is actually trig-
gered by the highly toxic soluble oligomeric species
of A [8–11]. Indeed, levels of soluble A oligomers
correlate well with dementia and AD severity [12–14].
The possible mechanisms underlying the neurotoxic
actions of A oligomers are under intense inves-
tigation: interaction with membranes, of both cells
and organelles, appears to be a critical first step
in the pathway to toxicity [15]. Numerous works
have demonstrated that A disturbs properties of
artificial and isolated biological membranes, and of
plasma membranes in living cells [16–19]. Specif-
ically, A oligomers can incorporate into neuronal
membranes to form calcium-permeable channels or
pores [20, 21]. The resultant excessive increase in
intracellular calcium then sets off a cascade of dele-
terious sequelae culminating in synaptic degeneration
and apoptosis [22–24]. In line with the concept that
A-induced membrane perforation is a fundamental
mechanism, reduction in ability of A oligomers to
bind lipid membranes was associated with decreased
toxicity to neuronal cells [25, 26]. Also, small-
molecule and peptide blockers of A calcium channels
potently protected neurons from cytotoxicity [27, 28].
Notwithstanding this significant body of evidence,
a demonstration that membrane perforation and/or
destabilization genuinely occur in vivo, resulting in
synaptotoxicity and neuronal cell death, is still lacking.
Several types of low-molecular-weight chemical
compounds have been previously shown to inhibit
A oligomer formation in vitro [29–33]. Of these,
polyphenols are an important class of beneficial
naturally-occurring molecules that are common con-
stituents in human diet and medicinal plants [34].
In most cases, foods contain complex mixtures of
polyphenols, which are often poorly characterized.
Fruit, tea, and red wine represent the main sources,
with daily intake averaging 1 g/day [35]. Polyphenols
essentially have several hydroxyl groups on aromatic
rings, thereby explaining their high antioxidant activity
[36]. In recent years, much attention has been paid to
the interaction between polyphenols and cellular mem-
branes, since it has been shown that they can interact
with and permeate lipid bilayers [37]. Some studies
have proposed that polyphenol molecules interact only
with the outer leaflet of bilayers [38], whilst others
report penetration of the lipid membrane by intercala-
tion of polyphenols between flexible acyl chains of the
phospholipids [39]. In particular, a rigidifying effect on
the bilayer consequently hindering permeabilization
by an A peptide, has been described [40].
Therefore, the anti-A aggregation effects of
polyphenols on the one hand, together with their capac-
ity to protect lipid membranes on the other, make them
attractive candidate molecules in AD therapy. As a
matter of fact, several recent studies involving dietary
supplementation with polyphenolic compounds have
consistently shown improvement in cognitive function
and AD pathology in transgenic mice [41–45]. Again,
recent epidemiological studies suggest that tea, one of
the most highly consumed polyphenolic beverages in
the world, might be a useful agent in the prevention or
treatment of AD/dementia [46–48].
In this study, a fluorescence-based vesicle permeabi-
lization assay was first established and characterized.
Next, the assay was used as a platform to screen a group
of low-molecular-weight compounds, as well as black
tea extract, for their ability to antagonize liposome
permeabilization by A42 peptide aggregates. Two dif-
ferent classes of small molecules were chosen, a group
of 15 naturally-occurring polyphenols and another
group of 8 synthetic N′-benzylidene-benzohydrazide
(NBB) derivatives. Black tea extract provided a rich
and complex milieu of bioactive polyphenols. Our
conclusions enabled us to gain insight into particu-
larly important structure-activity relationships which
may have implications for development of disease-
modifying therapy in AD.
MATERIALS AND METHODS
Materials
Purified synthetic A42 was purchased from rPep-
tide (Bogart, GA, USA); phospholipids were pur-
chased as a synthetic blend in chloroform: 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)/
1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPS)/
1,2-dioleoyl-snglycero-3-phosphocholine (DOPC) in
A.J. Gauci et al. / Polyphenols Protect Against Membrane Disruption by A42 769
a molar ratio of 5 : 3 : 2, from Avanti Polar Lipids
(Alabaster, AL, USA); Oregon Green® 488 BAPTA-1
(OG) was purchased from Invitrogen (Darmstadt,
Germany); M-PER® was obtained from Pierce
(Rockford, USA); apigenin (Api), baicalein (Baic),
black tea extract (BTE; >80% theaflavins), catechin
(Cat), (−)-epigallocatechin gallate (EGCG), fisetin
(Fis), fluorescein isothiocyanate conjugated to dex-
tran (FITC-dextran 40 kDa, FITC-dextran 70 kDa),
genistein (Gen), ginkgolide B (Gink), ionomycin,
morin (Mor), myricetin (Myr), nordihydroguaiaretic
acid (NDGA), purpurogallin trimethyl ether (Purp),
quercetin (Quer), rosmarinic acid (Rosm), resvera-
trol (Resv), thioflavin T (ThT) were all purchased
from Sigma-Aldrich (Munich, Germany); scutel-
larein (Scut) was obtained from Pharmasciences
Laboratories (Cour-bevoie, France); N′-benzylidene-
benzohydrazide (NBB) compounds were obtained
from Chembridge Corp. (San Diego, CA, USA). In
all cases, the purity of the compounds was >98%.
Polyphenols, NBB compounds and BTE were
prepared as stock solutions in DMSO and stored at
−20◦C. During the experiments, compounds were kept
away from light and used immediately after thawing.
Preparation of Aβ42 aggregates
Lyophilized A42 was dissolved in 10 mM NaOH
to 200 mM, and stored at −80◦C. The aggregation
protocol was based on that of Necula et al. [49],
which generates A oligomers and protofibrils. Thus,
oligomerization was achieved by incubating 45M
A42 in sterile PBS (pH 7.4) for 2 h at 37◦C. To mini-
mize evaporation, microfuge tubes (1.5 ml; Eppendorf,
Germany) were sealed with Whatman® adhesive film.
Thioﬂavin T ﬂuorescence assay
Thioflavin T (ThT) is a dye widely used for the
detection of cross--sheet structures in proteins, char-
acteristic of the amyloid fibrillar form. The ThT assay
was modified from El-Agnaf et al. [50]. Aggregation of
A42 was monitored over 24 h; at each sampling time, a
10l aliquot of the A42 solution was diluted in 190l
PBS (pH 7.5) containing 12M ThT. Fluorescence
was measured in black 96-well plates using an FLx800-
TBID microtiter plate reader (BioTek, Germany), with
excitation at 440 nm and emission at 490 nm. To allow
for background fluorescence, the fluorescence inten-
sity of a blank PBS solution was subtracted from all
readings. Data were measured in triplicates and aver-
aged for evaluations.
Analysis of Aβ42 aggregation by immunoblotting
Immunoblotting of A42 aggregation samples was
performed using precast NuPAGE® Novex 4–12% Bis-
Tris gels (Invitrogen, Darmstadt, Germany) according
to the manufacturer’s instructions. The samples were
prepared in NuPAGE® gel-loading buffer and resolved
by subjecting to electrophoresis in 1× MOPS SDS
buffer at 150 V for ∼1.5 h. Samples were not boiled
to avoid any oligomer dissociation. Transfer to nitro-
cellulose membrane (Hybond-ECL; General Electric,
USA) was carried out using XCell II™ Blot Mod-
ule (Invitrogen, Darmstadt, Germany), at 30 V for
1 h. After transfer, the membrane was immersed
in 5% blocking reagent and left overnight at 4◦C.
A was detected using 6E10 monoclonal antibody
(1 : 4000; Covance, Princeton, NJ, USA). Sites of pri-
mary antibody binding were detected with horseradish
peroxidase-conjugated secondary antibody (1 : 8000)
and blots were developed using ECLplus kit (Gen-
eral Electric, USA) according to the manufacturer’s
instructions.
Preparation of Small Unilamellar Vesicles (SUVs)
All vesicles used in our study were made up of the
phospholipids DOPE:DOPS:DOPC (5 : 3 : 2). These
vesicles have a net negative charge and lipid moieties
native to the neuronal environment [51]. Typically,
50g of lipids was thoroughly dried from a chlo-
roform solution under vacuum, to yield a thin lipid
film at the bottom of a glass vial. The thin film was
hydrated by adding 500l of a solution, 100 mM KCl,
10 mM MOPS/Tris, 1 mM EDTA (pH 7.0), containing
50M OG dye. The suspension was left to hydrate
for 60 min, with vortexing approximately every 15 min
until it turned very cloudy. Subsequently, 0.8 M Mega-
9 detergent was added to the suspension, and it was
vortexed gently until it appeared clear again. The lipid-
solution was then carefully loaded into Spectra/Por®
(Spectrum Labs, Breda, The Netherlands) membrane
tubing (pore size, 3.5 kDa) and subjected to dialysis for
6 h at room temperature against a buffer (5l) contain-
ing 100 mM KCl, 10 mM MOPS/Tris (pH 7.0). This
was followed by two successive overnight dialyses at
4◦C in the dark, with renewal of fresh buffer each time.
Liposomes were retrieved from the tubing and kept at
4◦C covered in aluminum foil.
A similar protocol was used to prepare FITC-
dextran loaded liposomes, but in this case the lipid film
was resuspended in 500l of 2 mg/ml FITC-dextran
(40 kDa; 70 kDa) whilst the untrapped FITC-dextran
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molecules were removed by 3–4 cycles of centrifu-
gation (22,000 g for 30 min).The size and uniformity
of the vesicle population were checked using a Zeta-
sizer Nano S dynamic light scattering (DLS) device
(Malvern, Worcestershire, UK). The vesicles were rel-
atively uniformly-sized with an average diameter of
67 ± 14 nm (data not shown), and hence categorized
as SUVs.
Liposome permeabilization assays
Liposome permeabilization assays indicate disrup-
tion of lipid vesicle membrane by release of an
encapsulated fluorophore [52]; in these experiments,
the calcium-sensitive fluorophore Oregon Green and
FITC-dextran molecules were used. In the case of OG,
increased fluorescence resulting from inward calcium
leakage and/or outward dye leakage indicates perme-
abilization of the liposomal membrane. In the case
of FITC-dextran, FITC-dextran molecules entrapped
in the liposomes are at high concentration and there-
fore self-quenching occurs; hence, leakage can be
monitored as a relief of quenching. Fluorescence mea-
surements were carried out using a microplate reader
(FLx800-TBID; BioTek, Germany) set with excita-
tion and emission wavelengths appropriate for the
fluorophore being used (for OG: excitation = 485 nm,
emission = 528 nm; for FITC: excitation = 495 nm,
emission = 520 nm). Readings were taken in black 96-
well microtiter plates (100l total well volume) at a
constant temperature of 22◦C. For kinetic readings,
the reader was programmed to take measurements at
regular intervals, typically for 15–20 min. Before each
reading, shaking for 30 s ensured adequate mixing of
the samples. Fluorescence intensity data was acquired
using KC JuniorTM software (BioTek, Germany).
Aggregated A42 was added to 25M liposomes
in assay buffer (1 mM CaCl2, 100 mM KCl, 10 mM
MOPS/Tris, 1 mM EDTA, pH 7.0). The apparent
percentage permeabilization value was calculated
according to the equation:
Permeabilization (%) = 100 × (F–F0)/(Fmax–F0),
where F denotes the maximum fluorescence inten-
sity of the measured sample; Fmax denotes the
maximum fluorescence intensity after the addition of
2M ionomycin (a calcium ionophore) in the case of
OG liposomes, or after the addition of 5% M-PER®
(a membrane detergent) in the case of FITC-dextran
liposomes; and F0 represents the fluorescence of intact
vesicles. Fluorescence intensity values are given in
RFU.
Assays for inhibition of Aβ42-induced liposome
permeabilization
1M aggregated A42 was incubated for 10 min
with compounds in assay buffer, prior to the addi-
tion of 25M liposomes. Disruption of lipid vesicles
by A in the presence of compound was calcu-
lated as a percentage of permeabilization caused by
A alone (theoretical maximum, 100%). Tested com-
pounds included: (i) 15 natural plant polyphenols
(typically at 50M): Api, Baic, Cat, EGCG, Fis, Gen,
Gink, Mor, Myr, NDGA, Purp, Quer, Rosm, Resv and
Scut; (ii) BTE (typically at 15g/ml); (iii) 8 NBB
derivatives (typically at 10M). At these typical con-
centrations none of the compounds had any significant
destabilizing effect on the liposomal membranes. Aut-
ofluorescence (where necessary) was measured for
each compound and was subtracted from the sample
well values.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 5 software (GraphPad Software, Inc.). Results
were expressed as the means and the standard error of
the mean (SEM) values, with n as the number of exper-
iments. Differences between means were determined
by unpaired Student’s t test. In all analyses, the null
hypothesis was rejected at the 0.05 level.
RESULTS
Characterization of Aβ42 aggregates
In a working hypothesis of AD, A aggregates
(typically, oligomers) directly damage neuronal and
synaptic membranes, leading to ionic dyshomeosta-
sis and eventually neurodegeneration. We therefore
wanted to generate A42 multimeric species, mainly
oligomers, that robustly compromised membrane
permeability of SUVs. The latter vesicles are a repre-
sentative model of native brain neuronal membranes,
having a net negative charge and similar phospholipid
composition.
The kinetics of A aggregation were first monitored
by measuring ThT fluorescence [53]. As expected,
there was a lag phase (with no change in cross--sheet
structure) during the first 2 h of incubation, followed
by a 4-h growth phase during which A42 pep-
tides aggregated into an increasingly fibrillar structure
(Fig. 1A). Such fibrillization kinetics are consistent
with a nucleated polymerization mechanism and hence
A.J. Gauci et al. / Polyphenols Protect Against Membrane Disruption by A42 771
Fig. 1. Characterization of amyloid- aggregate species. A) Aggregation kinetics of A42 peptide (45M) in PBS, pH 7.4, was monitored at
37◦C for 8 h in a Thioflavin T assay. After 2 h incubation, A aggregation (black squares) entered a phase of rapid kinetic growth representing
fibrillization. As expected, fluorescence measurements from PBS alone (white squares) remained unchanged. Values shown are means of
duplicate measurements (n = 2). B) A42 multimeric species (2g) generated by a 2 h aggregation protocol were separated on a 4–12% Tris-Bis
NuPAGE® gel and visualized using a monoclonal anti-A antibody (6E10). A strong band of oligomers ranging from 45–220 kDa is visible
(lane 2), in comparison to only monomers, dimers and trimers in the control, non-aggregated A42 (lane 1).
with previously published studies [49, 54]. Since we
were specifically interested in inducing damage to
phospholipid membranes by non-fibrillar A struc-
tures, only aggregates with low ThT fluorescence were
selected for further study.
Aβ42 oligomers evoke dose-dependent
permeabilization of DOPE:DOPS:DOPC
liposomes
A permeabilization assay was conducted, compar-
ing the perforation ability of A42 aggregates formed
after 1, 2, or 3 h incubation at 37◦C. The strongest
permeabilization effect was observed with the 2-h and
3-h aggregates (31.2% and 30%, respectively; Fig. 2),
whilst A42 peptides incubated for only 1 h had a sig-
nificantly weaker effect (23.9%; p = 0.027). Therefore,
on the basis of a combination of low ThT fluorescence
and robust membrane perforation, we opted for the
2 h aggregation to standardize our A oligomerization
protocol. Moreover, A42 multimers resulting from
a 2 h aggregation were separated and visualized by
immunoblotting (Fig. 1B). This confirmed formation
of oligomers ranging in size from 45–220 kDa, i.e.,
in the high-molecular-weight (HMW) range. These
oligomers were capable of inducing immediate
Fig. 2. Lipid vesicle permeabilization by A42 oligomers. 2.5M
A (aggregated for 1, 2, or 3 h) was added to 25M OG-filled
liposomes. Values are given as a percentage of ionomycin-induced
liposome permeabilization (theoretical max., 100%) and represent
means ± SEM (n = 3).
permeabilization of SUVs at 0.25–5M (in moles of
monomeric peptide), in most cases reaching a maxi-
mal effect within 15 min (Fig. 3). Permeabilization by
the A oligomers was calculated as percentage of the
ionomycin effect (a calcium ionophore): 15.7% ± 1.3
(0.25M), 24.7% ± 7.5 (0.5M), 25.8% ± 5.6
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Fig. 3. Kinetics of lipid vesicle permeabilization by A42 oligomers.
0.25 – 5M of A oligomers (in terms of moles of monomeric
protein) were added to OG-filled vesicles, as described in “Mate-
rials and Methods”. A dose-dependent effect upon the kinetics of
liposome permeabilization is shown. Conversely, 1M fresh (non-
aggregated) A42 left the lipid vesicles intact. Values shown in graph
were obtained from one experiment, out of at least three independent
measurements yielding quantitatively identical results.
(1.0M), 25.2% ± 5.0 (2.5M), and 30.6% ± 3.5
(5M). Importantly, lipid vesicles remained intact
following exposure to 1M fresh (non-aggregated)
A42 (Fig. 3). These results suggest that 0.5–1M
aggregated A42 was sufficient to cause defects in
the lipid bilayer that result in increased membrane
permeability. However, a 1M concentration was
more robust than 0.5M in giving a minimum perme-
abilization of more than 20% (0.5M: 24.7% ± 7.5;
1.0M: 25.8% ± 5.6). Therefore, 1M A42 was
typically chosen for subsequent experiments.
Finally, we wanted to characterize better the mode
of membrane destabilization by A, for instance,
whether by channel, pore formation or total disruption
of the vesicle membrane. Thus, a size-dependent flu-
orescence leakage assay was performed by preparing
liposomes containing FITC-dextrans of two different
molecular sizes (40 kDa or 70 kDa) and expos-
ing them to 1M A42 oligomers. The leakage
of the differentially-sized markers occurred as fol-
lows: 46.9% ± 2.6 (1 kDa), 38.3% ± 2.6 (40 kDa), and
39.3% ± 2.9 (70 kDa). Although there was a minor
decrease in leakage of the larger-sized dextrans, this
difference was not statistically significant (p = 0.07).
Inhibitory effects of natural polyphenols and BTE
on lipid vesicle permeabilization by Aβ42
oligomers
Having established a reproducible protocol for lipid
vesicle permeabilization by A42 oligomers, we pro-
ceeded to test the inhibitory effects of 15 plant
polyphenols and BTE. The compounds were allowed
to interact with pre-aggregated A42 before adding
liposomes; this approach allowed the compounds to
antagonize vesicle disruption by destabilizing the toxic
A species and/or by interfering with the binding of
A oligomers to the lipid vesicle membranes. The
results are summarized in Fig. 4A. Overall, addition
of plant polyphenols and BTE led to a decrease in
the vesicle permeabilization induced by A42 aggre-
gates alone, ranging from 90% permeabilization (weak
inhibitory effect) to 4% permeabilization (very strong
inhibitory effect). Compounds were hence classified as
follows:
• Group I - very strong inhibitors (<10% permeabi-
lization) BTE (4%).
• Group II - strong-to-moderate inhibitors (10–49%
permeabilization) Baic (22%), Api (27%), NDGA
(29%), Purp (35%) and Scut (45%).
• Group III - moderate-to-weak inhibitors (50–79%
permeabilization) Rosm (58%), EGCG (67%) and
Quer (73%).
• Group IV - weak inhibitors (80–95% permeabi-
lization) Myr (80%), Cat (80%), Gen (80%),
Mor (81%), Fis (82%), Gink (84%) and Resv
(90%).
A select group of three compounds from Groups
I and II (BTE, NDGA and Purp) were subsequently
tested for concentration-dependency in the range
10–100M (or 1–15g/ml in the case of BTE), using
the liposome permeabilization assay. NDGA remained
moderately effective even at 20M (60%), whilst
BTE was still a potent inhibitor at 5g/ml (<10%;
Fig. 4B).
Synergistic inhibition by pairwise combinations of
polyphenols
It was hypothesized that combinations of small-
molecule compounds could manifest a stronger,
synergistic, inhibitory effect than either compound
alone. Thus, pairwise associations of Api, NDGA,
and Purp were investigated for their inhibition of
A-induced lipid vesicle membrane destabilization
(Fig. 5). A synergistic effect was observed only with
the Purp-Api combination: 10M Purp alone (94%),
10M Api alone (80%), 10M Purp-Api (48%). The
other combinations showed at most additive, but not
synergistic, effects (data not shown).
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Fig. 4. Effects of polyphenols and black tea extract on lipid vesicle permeabilization by A42 oligomers. A) Polyphenols (50M) and BTE
(15g/ml) were incubated for 10 min with 1M pre-aggregated A42, after which 25M liposomes were added to monitor permeabilization.
Based on their inhibitory effects, the compounds were classified into 4 groups: very strong (black column), strong-to-moderate (dark gray
columns), moderate-to-weak (light gray columns), and weak (white columns). B) Concentration-dependent inhibition of liposome permeabi-
lization by purpurogallin trimetyl ether (Purp), NDGA and black tea extract (BTE). Liposome permeabilization in presence of compounds is
given as a percentage of the effect of A alone (% A42, y-axis). Values represent means ± SEM (n≥ 3); *p < 0.05, **p < 0.01, ***p < 0.005
versus A42.
Inhibition of Aβ42-induced lipid vesicle
permeabilization by synthetic N′-Benzylidene-
Benzohydrazide (NBB) compounds
Next, eight synthetic NBB compounds (NBB #1–8)
were also tested by the liposome permeabilization
inhibition assay (at 10M). The NBB compounds
were compared directly to the top natural polyphenols
identified by the previous screening (also at 10M).
This allowed identification of three NBB compounds
that were as potent as Baic, Api, and NDGA in
protecting lipid vesicle membranes from A perme-
abilization (Fig. 6): NBB #6 (80%), NBB #7 (80%)
and NBB #8 (67%).
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Fig. 5. Effect of compound combination on A-induced liposome
permeabilization. Paired combination of 10M Purp and 10M Api
reveals a synergistic potentiation of their inhibitory effect against
liposome permeabilization by A42. Values shown here are mean of
triplicate readings ± SEM (n = 2); ** p < 0.01, ***p < 0.005.
DISCUSSION
Maintenance of plasma membrane integrity is cru-
cial for neuronal function. In this regards, there is
accumulating evidence that prefibrillar A oligomers
are the primary neurotoxic species in AD [55] and that
disturbance of neuronal membranes is a likely first step
in the pathophysiological cascade initiated by these
oligomers [56]. Therefore, we first sought to generate
soluble high-molecular-weight A42 oligomers and
confirmed that they robustly compromised membranes
of model unilamellar liposomes at near-physiological
concentrations. Of note, ‘fresh’ A42 peptides (con-
sisting of monomers and very small oligomeric
species) were unable to induce vesicle permeabiliza-
tion. This is in agreement with several reports of
increased membrane conductance and permeability by
prefibrillar A oligomers, but not by near-monomeric
species [17, 57–59]. Large assemblies of Amolecules
have in fact been detected attached to live cell mem-
branes [60]. As a point of clarification, it cannot
be excluded that further conformational conversion
takes place upon interaction of the oligomers with
lipid membranes. For example, phosphatidylcholine
Fig. 6. Effect of 10M NBB derivates on A-induced liposome permeabilization. Lipid vesicle permeabilization was assessed by adding
25M liposomes following incubation of 10M NBB derivatives (1–8; gray columns) and solvent control (CTR; white column) with
1M pre-aggregated A42 for 10 min. For direct comparison, 10M Api and 10M Baic were included in the screen (black columns).
Values shown are percentage of A42 effect (% A42; y-axis). Values represent means ± SEM (n = 3); *p < 0.05, **p < 0.01, ***p < 0.005
versus A42.
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vesicles catalyzed the conversion of attached prefibril-
lar oligomers into pore-like annular protofibrils [61].
Most of the fluorescent dye leakage occurred rapidly
during the first 5 min, similar to what has been
described previously [62]. In order to explore the pos-
sibility that the A aggregates might be forming pores
within liposome membranes, the differences in leak-
age between 1-kDa, 40-kDa and 70-kDa fluorophores
was determined and found not to be statistically sig-
nificant, implying either complete disruption of the
membrane or a large-pore forming mechanism. Inter-
estingly, it has been reported that pores formed by A
in situ, in the neuronal cell membrane in AD brain,
had a lumen of ∼10 nm [63]. Such large A pores
would be expected to allow molecules, certainly up
to the size of 100 kDa, to leak out freely. Therefore,
a permeabilization mechanism involving pore forma-
tion by the HMW A42 aggregates cannot be excluded
a priori. It is relevant to point out here that pore-
forming proteins, like the bacterial toxin -hemolysin
and human perforin, share structural homology with
amyloid oligomers suggesting a common mechanism
of membrane permeabilization [64].
The ability of small molecule compounds and black
tea extract to protect phospholipid membranes from
disruption by A aggregates was tested using our per-
meabilization assay. Out of 15 natural polyphenols, 8
N′-benzylidene-benzohydrazide derivatives and BTE,
the most active was in fact the tea extract. At 5g/ml,
BTE still prevented the membrane-disordering effect
of A42 oligomers to less than 10% of control A
alone. Our assay result is supported by recent human
epidemiological and animal data suggesting that tea
drinking may help protect the aging brain and reduce
the incidence of dementia or AD [65]. Thus, inter-
fering with oligomer-induced lipid membrane damage
may represent a key modality in the treatment of AD
neurodegeneration.
The basic flavonoid structure is the flavan core,
which consists of a 15 carbon skeleton (C6-C3-C6),
arranged in three rings labeled as A, B, and C (Fig. 7).
The various classes of flavonoids differ in the level
of oxidation and pattern of substitution of the C ring.
These include the flavonols (e.g., Fis, Mor, Myr, Quer),
the flavanols (e.g., EGCG, Cat), the flavones (e.g.,
Api, Baic, Scut), and the isoflavones (e.g., Gen). Indi-
vidual compounds within a class differ in the pattern
of substitution of the A and B rings. Apart from
the very strong activity of BTE, five small-molecule
polyphenols were classified as “strong-to-moderate”
inhibitors since they decreased liposome permeabi-
lization to 10–49%. Notably, of these five com-
pounds, three are flavones: 5,6,7-trihydroxyflavone
(Baic), 4′,5,7-trihydroxyflavone (Api), and 4′,5,6,7-
tetrahydroxyflavone (Scut). Examining these three
structures, a common 5,7-dihydroxyflavone scaffold
appears to be a prominent feature (Fig. 7). In contrast,
the weaker flavonols Fis, Mor, Myr, and Quer possess
a hydroxyl group attached to C3. Moreover, Cat and
EGCG, as well as the isoflavone Gen, have the B ring
of the flavonoid molecule attached to C3. Evidently,
substitutions at the C3 position have profound nega-
tive effects on the ability of the polyphenol molecule
to attenuate membrane permeabilization.
Another strong inhibitor of lipid membrane damage
by the A42 oligomers is NDGA, which shares a 6,7-
dihydroxyphenyl ring structure with the A ring of Baic
and Api (Fig. 7). Interestingly, dihydroxyphenyl rings
are a recurring feature of the three synthetic NBB com-
pounds (NBB #6–8; 307F06, 301C09, and 293G02,
respectively) with inhibitory activities similar to Api,
Baic, and NDGA. To conclude, intuitive recognition
of the structural relationships associated with highest
inhibitory activity allows derivation of the ‘scaffold
tree’ shown in Fig. 7: essentially, a dihydroxyphenyl
ring alone, or as part of a flavone module with a pre-
ferred maximum of 3 hydroxyl groups, is particularly
adapted for protection against membrane damage by
A oligomers. These structure-activity relationships
may also be of importance when considering treatment
with combinations of small-molecule compounds. For
instance, we noted a synergistic effect between Api
and Purp: the paired compounds at 10M were almost
as strong as either compound alone at five times that
concentration. The synergism implies a different mode
of action of these two molecules, which represent in
fact a combination of an apolar (Purp) and polar (Api)
chemical structures.
The molecular mechanisms underlying preserva-
tion of membrane integrity by BTE and phenolic
compounds is currently under investigation. First of
all, rescue may depend upon interaction of com-
pounds with the oligomers themselves. This would
lead to dissociation and/or remodeling of the oligomers
into harmless A species. Substantial data has been
published on the ability of the studied inhibitors
to inhibit A aggregation and/or destabilize formed
assemblies in vitro [66–69]. Importantly, however,
in all of these assays A aggregation was tested in
the absence of lipids. Indeed, when comparing these
reported anti-amyloidogenic properties of polyphe-
nols, on one hand, with our results from the liposome
776 A.J. Gauci et al. / Polyphenols Protect Against Membrane Disruption by A42
Fig. 7. Chemical structures of the top small-molecule compounds inhibiting A-induced liposome permeabilization. The flavone polyphenols:
apigenin (4′,5,7-trihydroxyflavone), baicalein (5,6,7-trihydroxyflavone) and scutellarein (4′,5,6,7-tetrahydroxyflavone). A shared criterion is
thus the 5,7-dihydroxyflavone structure; note the15 carbon skeleton (C6-C3-C6) of a flavan core, arranged in three rings labeled as A, B, and C.
Another strong inhibitor was found to be the polyphenol NDGA, which shares a 6,7-dihydroxyphenyl ring structure with the A ring of baicalein
and apigenin. Dihydroxyphenyl rings are common to the three top-scoring N′-benzylidene-benzohydrazide compounds (307F06, 301C09 and
293G02).
permeabilization assay, on the other, we find no sig-
nificant correlation between the two. For example,
Api was found to be a very weak inhibitor of A42
aggregation (IC50 > 40M), and Baic (IC50 = 5.3M)
was at least an order of magnitude less potent than
other flavonoids such as Myr (IC50 = 0.67M), Mor
(IC50 = 0.4M), Quer (IC50 = 0.72M), or EGCG
(IC50 = 0.18M). These observations seem to suggest,
therefore, that mechanisms involving direct binding of
the compounds to A multimeric structures leading
to their complete disassembly [31] are not likely to
be primarily involved. The possibility still remains,
notwithstanding, that compounds like Api and Baic
remodel the soluble oligomers into larger aggregates
that are non-toxic to membranes [70]. The excep-
tion appears to be NDGA, which has a known potent
anti-amyloidogenic and fibril destabilizing activity
(IC50 = 0.74–1.1M0 [69]. NDGA is composed dif-
ferently from the flavones, and has two relatively polar
aromatic groups (the dihydroxyphenyl rings discussed
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above) connected by a rigid linker. Interestingly, effec-
tive molecules from the NBB derivates (NBB #6–8)
have an analogous structure to NDGA, with a dihy-
droxyphenyl ring at one end of the molecule, a phenyl
ring at the other and a central linker. It is also striking
that the top NBB compound in our liposome perme-
abilization assay, NBB #8 (293G02), correlates nicely
with previously published findings: 293G02 was also
the best NBB compound to demonstrate anti-prion
activity in a high-throughout screening assay [71], to
potently inhibit polyQ aggregation [72] and to inter-
fere with alpha-synuclein oligomer formation in living
cells [73].
Another possible mechanism would involve mod-
ulation of the oligomer-membrane interaction by the
compounds, particularly the polyphenols. A flavonoid-
dependent effect on the lipid bilayer may explain, in
part, the preservation of membrane integrity by the
compounds. It has been shown recently that flavonoids
partially penetrate bilayer membranes, resulting in a
strong rigidifying effect on the bilayer structure. Con-
sequently, membranes exposed to flavonoids loose the
ability to interact with A peptide [40].
CONCLUSION
We report here a novel study on the effects of
small-molecule natural and synthetic compounds, and
black tea extract, on the permeabilization of lipid
vesicles by A42 oligomers. Based upon our data,
we encourage more in-depth studies on the poten-
tial disease-modifying effects of black tea in AD.
Apart from tea extract, the common structural crite-
rion shared by the potent inhibitors (Api, Baic, Scut,
NDGA, 307F06, 301C09, and 293G02) is the presence
of a dihydroxyphenyl ring structure, alone or as part of
a flavone scaffold. Having identified this active skele-
ton, combinatorial chemistry can be used as a means for
further structural compound optimization [74]. Given
that neuronal phospholipid membranes are consid-
ered a primary target of A oligomers, it follows that
development of such compounds would help meet the
momentous therapeutic challenge represented by AD.
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